Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
IDH1 inhibitor

Ivosidenib (Specialist drug)

Brand names: Tibsovo

Ivosidenib is an oral specialist haemato-oncology agent licensed for IDH1-mutated acute myeloid leukaemia and cholangiocarcinoma; in a rheumatology setting it is encountered only as a comorbidity medication requiring shared-care awareness, not as an antirheumatic drug.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a targeted inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), reducing the oncometabolite 2-hydroxyglutarate and promoting malignant cell differentiation.

Prescribing in practice

  • QT-interval prolongation is a key safety concern, so ECG monitoring and avoidance of other QT-prolonging drugs are required.
  • Differentiation syndrome, which can be life-threatening, may occur in leukaemia treatment and needs urgent recognition and corticosteroid management.
  • It is a CYP3A4 substrate and can affect other drug exposures, so interactions must be checked against current prescribing references.

Monitoring

Monitor ECG and electrolytes, and watch for features of differentiation syndrome, with management directed by the specialist team and the SPC.

Counselling the patient

  • Report breathlessness, swelling, fever or palpitations promptly.
  • Tell your team about all other medicines because of heart-rhythm interactions.
  • Attend scheduled ECG and blood monitoring.

Evidence & guidelines

Approval is based on trials in IDH1-mutated acute myeloid leukaemia and cholangiocarcinoma showing meaningful response rates.

Reference: NICE TA779/TA983; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways